Next 10 |
2024-05-01 14:46:13 ET United Therapeutics Corporation (UTHR) Q1 2024 Earnings Conference Call May 1, 2024 09:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz -...
2024-05-01 06:37:13 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quar...
2024-04-30 11:53:23 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 Please replace the photo for release dated April 24, 2024 wi...
2024-04-24 10:23:46 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 United Therapeutics Corporation (Nasdaq: UTHR ), a publi...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fib...
2024-03-31 08:00:00 ET More on Liquidia Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Liquidia gains after court win in pat...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, b...
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday. Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply ...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quar...